RNAZ
TransCode Therapeutics, Inc. NASDAQ$7.74
Mkt Cap $7.1M
52w Low $6.08
11.1% of range
52w High $20.99
50d MA $9.05
200d MA $9.92
P/E (TTM)
-0.1x
EV/EBITDA
0.4x
P/B
0.5x
Debt/Equity
0.0x
ROE
-335.4%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
1.50
50d MA
$9.05
200d MA
$9.92
Avg Volume
208.2K
About
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programme…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | AMC | -10.08 | -18.58 | -62.9% | 8.91 | -2.5% | -2.4% | -1.2% | -0.2% | -0.4% | -3.5% | — |
| Nov 14, 2025 | AMC | -9.24 | -5.49 | +40.6% | 9.24 | -2.6% | +1.8% | -2.3% | -2.7% | -7.4% | -6.5% | — |
| Aug 14, 2025 | AMC | -8.68 | -4.94 | +43.1% | 11.05 | +5.9% | -2.4% | -5.0% | -11.3% | -8.3% | -14.8% | — |
| May 14, 2025 | AMC | -3.21 | -16.81 | -423.7% | 9.71 | -15.0% | -21.2% | -16.0% | -31.0% | -27.8% | -18.2% | — |
| Mar 28, 2025 | AMC | -105.93 | -16.61 | +84.3% | 13.72 | -7.4% | +1.0% | +10.4% | +7.9% | -5.7% | -6.5% | — |
| Nov 14, 2024 | AMC | -16.17 | -5.28 | +67.3% | 226.52 | -3.1% | -3.0% | -5.8% | -6.4% | -4.1% | +8.5% | — |
| Aug 14, 2024 | AMC | -19.14 | -24.42 | -27.6% | 147.28 | +1.3% | +9.9% | +17.1% | +18.6% | +20.9% | +22.8% | — |
| May 15, 2024 | AMC | -23.10 | -21.45 | +7.1% | 521.64 | -0.8% | +9.7% | +42.6% | +47.6% | +54.8% | +78.9% | — |
| Mar 29, 2024 | AMC | -10.80 | -99.99 | -825.8% | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -1980.20 | -2217.82 | -12.0% | 8200.64 | -1.2% | -9.3% | -18.0% | -17.3% | -27.7% | -27.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.14 | $10.95 | -1.7% | -10.4% | -31.5% | -24.6% | -21.8% | -21.1% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.99 | $17.89 | -10.5% | -27.3% | -23.8% | -23.5% | -20.1% | -25.5% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $222.88 | $213.92 | -4.0% | -13.3% | +3.8% | -4.8% | -5.2% | -6.3% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $175.28 | $222.04 | +26.7% | +27.2% | +10.2% | +31.9% | +21.1% | +20.6% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $123.76 | $81.76 | -33.9% | -38.0% | -38.9% | -40.5% | -43.2% | -44.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $226.52 | $219.52 | -3.1% | -3.0% | -5.8% | -6.4% | -4.1% | +8.5% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $435.40 | $427.00 | -1.9% | -3.5% | -12.7% | -11.3% | -16.8% | -25.1% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $178.08 | $177.52 | -0.3% | -4.1% | -7.1% | -6.9% | -5.7% | -8.0% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $147.28 | $149.24 | +1.3% | +9.9% | +17.1% | +18.6% | +20.9% | +22.8% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1254.40 | $1113.28 | -11.2% | -25.0% | -15.6% | -8.1% | -16.2% | -30.0% |
Recent Filings
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
RNAZ's new material agreement with YA II PN, LTD. could signal partnership or financing that affects growth prospects, making this worth monitoring for detailed terms affecting shareholder value.
Apr 7
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
RNAZ's delayed annual report filing signals potential financial distress or operational problems, likely triggering exchange delisting concerns and causing investors to reassess the company's viability and governance.
Mar 31
8-K · 8.01
!! High
TransCode Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
TransCode Therapeutics announced a material event requiring SEC disclosure, though specific details weren't provided in the summary excerpt.
Mar 3
8-K · 7.01
! Medium
TransCode Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
TransCode Therapeutics published research on its RIG-I agonist cancer immunotherapy platform in Molecular Imaging and Biology, potentially validating its scientific approach and strengthening intellectual property positioning.
Feb 23
8-K · 7.01
! Medium
TransCode Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
TransCode Therapeutics advanced its lead cancer candidate TTX-MC138 toward Phase 2a testing through an FDA IND amendment submission, potentially expanding clinical development and de-risking the pipeline.
Feb 5
Data updated apr 26, 2026 11:12pm
· Source: massive.com